Advances in Immune Checkpoint Inhibitors for Gynecological Malignant Solid Tumors

doi:10.12280/gjfckx.20220578

Abstract

Abstract:

Gynecological solid cancers severely threaten women′s health. Adjuvant treatment such as radiotherapy and chemotherapy for advanced, recurrent and metastatic gynecological tumors is ineffective and the prognosis is poor. In recent years, immunotherapy based on immune checkpoint inhibitors has shown good efficacy in the treatment of malignant solid tumors, and also provides new treatment options for patients with gynecological malignant solid tumors. However, the effect of immune checkpoint inhibitors monotherapy in the failure of traditional platinum-based chemotherapy is poor, which may be related to the difficulty of effective immune response in patients with impaired immune system after multi-cycle chemotherapy. Many clinical studies have shown that immune checkpoint inhibitors combined with platinum-based chemotherapy and pre-application of immune checkpoint inhibitors can benefit patients with advanced, recurrent and metastatic gynecological malignant solid tumors. This article reviews the application progress of immune checkpoint inhibitors in gynecological malignant solid tumors.

Key words: Immune checkpoint inhibitors, Immunotherapy, Uterine cervical neoplasms, Endometrial neoplasms, Ovarian neoplasms, Combined modality therapy

LIU De-gao, ZHANG Shu-rong, GAO Yue-wen, ZOU Yong-hui, LI Chang-zhong. Advances in Immune Checkpoint Inhibitors for Gynecological Malignant Solid Tumors[J]. Journal of International Obstetrics and Gynecology, 2022, 49(6): 601-605.

References 32

[1]	Pirš B, Škof E, Smrkolj V, et al. Overview of Immune Checkpoint Inhibitors in Gynecological Cancer Treatment[J]. Cancers (Basel), 2022, 14(3):631. doi: 10.3390/cancers14030631. doi: 10.3390/cancers14030631
[2]	Ladbury C, Germino E, Novak J, et al. Combination radiation and immunotherapy in gynecologic malignancies-a comprehensive review[J]. Transl Cancer Res, 2021, 10(5):2609-2619. doi: 10.21037/tcr-20-3019. doi: 10.21037/tcr-20-3019 pmid: 35116574
[3]	Xia C, Xu X, Zhao X, et al. Effectiveness and cost-effectiveness of eliminating cervical cancer through a tailored optimal pathway: a modeling study[J]. BMC Med, 2021, 19(1):62. doi: 10.1186/s12916-021-01930-9. doi: 10.1186/s12916-021-01930-9 pmid: 33653331
[4]	He R, Zhu B, Liu J, et al. Women′s cancers in China: a spatio-temporal epidemiology analysis[J]. BMC Womens Health, 2021, 21(1):116. doi: 10.1186/s12905-021-01260-1. doi: 10.1186/s12905-021-01260-1
[5]	Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J (Engl), 2022, 135(5):584-590. doi: 10.1097/CM9.0000000000002108. doi: 10.1097/CM9.0000000000002108
[6]	Guimarães YM, Godoy LR, Longatto-Filho A, et al. Management of Early-Stage Cervical Cancer: A Literature Review[J]. Cancers (Basel), 2022, 14(3):575. doi: 10.3390/cancers14030575. doi: 10.3390/cancers14030575
[7]	Wright JD, Matsuo K, Huang Y, et al. Prognostic Performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines[J]. Obstet Gynecol, 2019, 134(1):49-57. doi: 10.1097/AOG.0000000000003311. doi: 10.1097/AOG.0000000000003311 pmid: 31188324
[8]	Moore DH, Tian C, Monk BJ, et al. Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study[J]. Gynecol Oncol, 2010, 116(1):44-49. doi: 10.1016/j.ygyno.2009.09.006. doi: 10.1016/j.ygyno.2009.09.006 pmid: 19853287
[9]	Chung HC, Ros W, Delord JP, et al. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study[J]. J Clin Oncol, 2019, 37(17):1470-1478. doi: 10.1200/JCO.18.01265. doi: 10.1200/JCO.18.01265 pmid: 30943124
[10]	Naumann RW, Hollebecque A, Meyer T, et al. Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase Ⅰ/ⅡCheckMate 358 Trial[J]. J Clin Oncol, 2019, 37(31):2825-2834. doi: 10.1200/JCO.19.00739. doi: 10.1200/JCO.19.00739 pmid: 31487218
[11]	Meng Y, Liang H, Hu J, et al. PD-L1 Expression Correlates With Tumor Infiltrating Lymphocytes And Response To Neoadjuvant Chemotherapy In Cervical Cancer[J]. J Cancer, 2018, 9(16):2938-2945. doi: 10.7150/jca.22532. doi: 10.7150/jca.22532 pmid: 30123362
[12]	Enwere EK, Kornaga EN, Dean M, et al. Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer[J]. Mod Pathol, 2017, 30(4):577-586. doi: 10.1038/modpathol.2016.221. doi: 10.1038/modpathol.2016.221
[13]	Shao C, Li G, Huang L, et al. Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors[J]. JAMA Netw Open, 2020, 3(10):e2025109. doi: 10.1001/jamanetworkopen.2020.25109. doi: 10.1001/jamanetworkopen.2020.25109
[14]	Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer[J]. N Engl J Med, 2021, 385(20):1856-1867. doi: 10.1056/NEJMoa2112435. doi: 10.1056/NEJMoa2112435
[15]	周晖, 刘昀昀, 罗铭, 等. 《2022 NCCN子宫颈癌临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2021, 37(12):1220-1226. doi: 10.19538/j.fk2021120112. doi: 10.19538/j.fk2021120112
[16]	Grau JF, Farinas-Madrid L, Oaknin A. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030)[J]. Int J Gynecol Cancer, 2020, 30(1):139-143. doi: 10.1136/ijgc-2019-000880. doi: 10.1136/ijgc-2019-000880 pmid: 31645423
[17]	Tung HJ, Huang HJ, Lai CH. Adjuvant and post-surgical treatment in endometrial cancer[J]. Best Pract Res Clin Obstet Gynaecol, 2022, 78:52-63. doi: 10.1016/j.bpobgyn.2021.06.002. doi: 10.1016/j.bpobgyn.2021.06.002
[18]	Park JY, Lee JY, Lee YY, et al. Major clinical research advances in gynecologic cancer in 2021[J]. J Gynecol Oncol, 2022, 33(2):e43. doi: 10.3802/jgo.2022.33.e43. doi: 10.3802/jgo.2022.33.e43
[19]	Banz-Jansen C, Helweg LP, Kaltschmidt B. Endometrial Cancer Stem Cells: Where Do We Stand and Where Should We Go?[J]. Int J Mol Sci, 2022, 23(6):3412. doi: 10.3390/ijms23063412. doi: 10.3390/ijms23063412
[20]	Mullen MM, Mutch DG. Endometrial Tumor Immune Response: Predictive Biomarker of Response to Immunotherapy[J]. Clin Cancer Res, 2019, 25(8):2366-2368. doi: 10.1158/1078-0432.CCR-18-4122. doi: 10.1158/1078-0432.CCR-18-4122 pmid: 30692101
[21]	Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study[J]. J Clin Oncol, 2020, 38(1):1-10. doi: 10.1200/ JCO.19.02105. doi: 10.1200/JCO.19.02105 pmid: 31682550
[22]	Li S, Chen P, Yang QK. Retraction notice[J]. J Bone Oncol, 2020, 21:100284. doi: 10.1016/j.jbo.2020.100284. doi: 10.1016/j.jbo.2020.100284
[23]	谢玲玲, 林荣春, 林仲秋. 《2022 NCCN子宫肿瘤临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2021, 37(12):1227-1233. doi: 10.19538/j.fk2021120113. doi: 10.19538/j.fk2021120113
[24]	Peremiquel-Trillas P, Frias-Gomez J, Alemany L, et al. Predicting Ovarian-Cancer Burden in Catalonia by 2030: An Age-Period-Cohort Modelling[J]. Int J Environ Res Public Health, 2022, 19(3):1404. doi: 10.3390/ijerph19031404. doi: 10.3390/ijerph19031404
[25]	Redondo A, Guerra E, Manso L, et al. SEOM clinical guideline in ovarian cancer (2020)[J]. Clin Transl Oncol, 2021, 23(5):961-968. doi: 10.1007/s12094-020-02545-x. doi: 10.1007/s12094-020-02545-x pmid: 33515422
[26]	谢幸, 孔北华, 段涛. 妇产科学[M]. 北京: 人民卫生出版社, 2019.
[27]	Hamanishi J, Takeshima N, Katsumata N, et al. Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)[J]. J Clin Oncol, 2021, 39(33):3671-3681. doi: 10.1200/JCO.21.00334. doi: 10.1200/JCO.21.00334
[28]	Moore KN, Bookman M, Sehouli J, et al. Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage Ⅲ or Ⅳ Ovarian Cancer: Placebo-Controlled Randomized Phase 2 Trial (IMagyn050/GOG 3015/ENGOT-OV39)[J]. J Clin Oncol, 2021, 39(17):1842-1855. doi: 10.1200/JCO.21.00306. doi: 10.1200/JCO.21.00306
[29]	卢淮武, 吴斌, 许妙纯, 等. 《2022 NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2022, 38(3):310-318. doi:10.19538/j.fk2022030113. doi: 10.19538/j.fk2022030113
[30]	Maiorano BA, Lorusso D, Maiorano M, et al. The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy[J]. Int J Mol Sci, 2022, 23(7):3871. doi: 10.3390/ijms23073871. doi: 10.3390/ijms23073871
[31]	Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade[J]. N Engl J Med, 2018, 378(2):158-168. doi: 10.1056/NEJMra1703481. doi: 10.1056/NEJMra1703481
[32]	中华医学会妇科肿瘤学分会, 孔北华, 刘继红, 等. 妇科肿瘤免疫检查点抑制剂临床应用指南[J]. 协和医学杂志, 2021, 12(6):854-880. doi: 10.12290/xhyxzz.2021-0683. doi: 10.12290/xhyxzz.2021-0683